Hypermethylation of the TGF-β target, ABCA1 is associated with poor prognosis in ovarian cancer patients
Authors:
- Jian-Liang ChouJCJian-Liang Chou
- Rui-Lan HuangRHRui-Lan Huang
- Jacqueline ShayJSJacqueline Shay
- Lin-Yu ChenLCLin-Yu Chen
- Sheng-Jie LinSLSheng-Jie Lin
- Pearlly S YanPYPearlly S Yan
- Wei-Ting ChaoWCWei-Ting Chao
- Yi-Hui LaiYLYi-Hui Lai
- Yen-Ling LaiYLYen-Ling Lai
- Tai-Kuang ChaoTCTai-Kuang Chao
- Cheng-I LeeCLCheng-I Lee
- Chien-Kuo TaiCTChien-Kuo Tai
Open Access
- 14 January 2015
- journal article
- research article
- Published by Springer Nature in Clinical Epigenetics
- Vol. 7 (1) , 1-11
Abstract
The dysregulation of transforming growth factor-β (TGF-β) signaling plays a crucial role in ovarian carcinogenesis and in maintaining cancer stem cell properties. Classified as a member of the ATP-binding cassette (ABC) family, ABCA1 was previously identified by methylated DNA immunoprecipitation microarray (mDIP-Chip) to be methylated in ovarian cancer cell lines, A2780 and CP70. By microarray, it was also found to be upregulated in immortalized ovarian surface epithelial (IOSE) cells following TGF-β treatment. Thus, we hypothesized that ABCA1 may be involved in ovarian cancer and its initiation. We first compared the expression level of ABCA1 in IOSE cells and a panel of ovarian cancer cell lines and found that ABCA1 was expressed in HeyC2, SKOV3, MCP3, and MCP2 ovarian cancer cell lines but downregulated in A2780 and CP70 ovarian cancer cell lines. The reduced expression of ABCA1 in A2780 and CP70 cells was associated with promoter hypermethylation, as demonstrated by bisulfite pyro-sequencing. We also found that knockdown of ABCA1 increased the cholesterol level and promoted cell growth in vitro and in vivo. Further analysis of ABCA1 methylation in 76 ovarian cancer patient samples demonstrated that patients with higher ABCA1 methylation are associated with high stage (P = 0.0131) and grade (P = 0.0137). Kaplan-Meier analysis also found that patients with higher levels of methylation of ABCA1 have shorter overall survival (P = 0.019). Furthermore, tissue microarray using 55 ovarian cancer patient samples revealed that patients with a lower level of ABCA1 expression are associated with shorter progress-free survival (P = 0.038). ABCA1 may be a tumor suppressor and is hypermethylated in a subset of ovarian cancer patients. Hypermethylation of ABCA1 is associated with poor prognosis in these patients.Keywords
This publication has 33 references indexed in Scilit:
- Anticancer Activity of the Cholesterol Exporter ABCA1 GeneCell Reports, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Anticancer Efficacy of Simvastatin on Prostate Cancer Cells and Tumor Xenografts Is Associated with Inhibition of Akt and Reduced Prostate-Specific Antigen ExpressionThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Combined Inhibitory Effects of Celecoxib and Fluvastatin on the Growth of Human Hepatocellular Carcinoma Xenografts in Nude MiceJournal of International Medical Research, 2010
- Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevanceBMC Cancer, 2010
- Promoter hypermethylation of FBXO32, a novel TGF-β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancerLaboratory Investigation, 2010
- TGF-β1 Up-Regulates Expression of ABCA1, ABCG1 and SR-BI through Liver X Receptor α Signaling Pathway in THP-1 Macrophage-Derived Foam CellsJournal of Atherosclerosis and Thrombosis, 2010
- An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modulesBMC Systems Biology, 2009
- Characterization of LMX‐1A as a metastasis suppressor in cervical cancerThe Journal of Pathology, 2009
- Regulation of the mevalonate pathwayNature, 1990